Predictors of rheumatic immune ‐related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

ConclusionWe identified novel predictors of rheum-irAEs that included melanoma, genitourinary cancer, pre-existing autoimmune disease, combination ICI, and glucocorticoid use. The proportion of cancer patients experiencing rheum-irAEs may be even higher than we report since we used stringent criteria to identify cases. These findings may identify cancer patients at risk of developing rheum-irAEs andde novo inflammatory arthritis and inform pathogenesis.

Source: Arthritis and Rheumatology - August 16, 2021 Category: Rheumatology Authors: Amy Cunningham ‐Bussel, Jiaqi Wang, Lauren C. Prisco, Lily W. Martin, Kathleen M.M. Vanni, Alessandra Zaccardelli, Mazen Nasrallah, Lydia Gedmintas, Lindsey A. MacFarlane, Nancy A. Shadick, Mark M. Awad, Osama Rahma, Nicole R. LeBoeuf, Elle Tags: FULL LENGTH Source Type: research